Stifel Nicolaus Reaffirms Their Buy Rating on Celcuity (CELC)

In a report released today, Bradley Canino from Stifel Nicolaus maintained a Buy rating on Celcuity (CELC – Research Report), with a price target of $40.00. The company’s shares closed yesterday at $18.16.

Canino covers the Healthcare sector, focusing on stocks such as Blueprint Medicines, Kura Oncology, and Merus. According to TipRanks, Canino has an average return of 7.6% and a 47.32% success rate on recommended stocks.

Celcuity has an analyst consensus of Strong Buy, with a price target consensus of $30.33, a 67.02% upside from current levels. In a report released today, Needham also maintained a Buy rating on the stock with a $24.00 price target.

CELC market cap is currently $439.5M and has a P/E ratio of -6.64.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Celcuity (CELC) Company Description:

Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the targeted therapy that treats it. The company was founded in January 2012 by Brian Sullivan and Lance Laing and is headquartered in Minneapolis, MN.